Recombinant Factor VII for Intractable Postpartum Haemorrhage

Completed

• Conditions: Post Partum Hemorrhage
• Interventions: Drug: recombinant factor VIIa

• Registration Number: NCT05298826
• Lead Sponsor: Aljazeera Hospital

Brief Summary

Postpartum haemorrhage remains at the top of the causes of maternal deaths in both developed and developing countries .

Detailed Description

Major postpartum haemorrhage is a dangerous complication that accounts for the highest maternal morbidity rate

Study Timeline

• Study Start: 2019-06-01
• Primary Completion: 2020-01-01
• Study Completion: 2020-01-10
• Status Verified: 2022-03
• Study First Submitted: 2022-03-18
• Study First Submitted QC: 2022-03-18
• Last Update Submitted: 2022-03-18
• Study First Posted: 2022-03-28
• Last Update Posted: 2022-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 41

Inclusion Criteria

• Women with severe resistant postpartum hemorage

Exclusion Criteria

• women without postpartum hemorage

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Junior staff has started the management and called for the senior staff.	recombinant factor VIIa	-
senior staff. managed the case from the start	recombinant factor VIIa	-

Primary Outcome Measures

Name	Time	Method
The number of women who had hysterectomy	24 hours	number of women resistant to the treatment and needed hysterectomy

Trial Locations

Locations (1)

Doaaa Alaa; 🇪🇬 Cairo, Egypt